Phase 1 × Completed × Carcinoma, Non-Small-Cell Lung × Clear all A Study of DF6002 Alone and in Combination With Nivolumab
Phase 1 Completed
170 enrolled
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Phase 1 Completed
78 enrolled
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Phase 1 Completed
25 enrolled 14 charts
MK-1084-009
Phase 1 Completed
28 enrolled
Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Completed
41 enrolled
Intratumoral Cisplatin for Resectable NSCLC
Phase 1 Completed
6 enrolled 6 charts
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Phase 1 Completed
172 enrolled 33 charts
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
Phase 1 Completed
18 enrolled
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Phase 1 Completed
22 enrolled
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Phase 1 Completed
23 enrolled 11 charts
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Phase 1 Completed
168 enrolled
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Phase 1 Completed
28 enrolled
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
Phase 1 Completed
8 enrolled
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Phase 1 Completed
48 enrolled
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Phase 1 Completed
53 enrolled
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Phase 1 Completed
60 enrolled 91 charts
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
Phase 1 Completed
52 enrolled 14 charts
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
Phase 1 Completed
39 enrolled 18 charts
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Completed
18 enrolled
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Phase 1 Completed
252 enrolled 47 charts
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1 Completed
145 enrolled
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Phase 1 Completed
45 enrolled
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
AMPLIFY-201
Phase 1 Completed
25 enrolled 15 charts
ARC-12
Phase 1 Completed
94 enrolled
MEK162
Phase 1 Completed
13 enrolled 11 charts
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Phase 1 Completed
134 enrolled 37 charts
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Phase 1 Completed
146 enrolled 38 charts
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1 Completed
185 enrolled 28 charts
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1 Completed
26 enrolled 21 charts
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Phase 1 Completed
32 enrolled 14 charts
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Phase 1 Completed
31 enrolled
DISCOVER
Phase 1 Completed
11 enrolled
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
Phase 1 Completed
15 enrolled 19 charts
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Phase 1 Completed
17 enrolled
TGRX-326 Pharmacokinetic Food Effect Bioavailability Study
Phase 1 Completed
24 enrolled
Continued Access to RXDX-105
Phase 1 Completed
3 enrolled
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
Phase 1 Completed
13 enrolled 12 charts
MIDRIXNEO
Phase 1 Completed
6 enrolled
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Phase 1 Completed
112 enrolled
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Phase 1 Completed
269 enrolled